Mephedrone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Mephedrone
DrugBank Accession Number
DB13108
Background

Mephedrone has been investigated in Alcohol-Related Disorders and Amphetamine-Related Disorders.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 177.2429
Monoisotopic: 177.115364107
Chemical Formula
C11H15NO
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololThe therapeutic efficacy of Acebutolol can be decreased when used in combination with Mephedrone.
AceclofenacThe risk or severity of hypertension can be increased when Aceclofenac is combined with Mephedrone.
AcemetacinThe risk or severity of hypertension can be increased when Mephedrone is combined with Acemetacin.
AcetazolamideAcetazolamide may decrease the excretion rate of Mephedrone which could result in a higher serum level.
AcetophenazineAcetophenazine may decrease the stimulatory activities of Mephedrone.
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Alkyl-phenylketones
Alternative Parents
Phenylpropanes / Benzoyl derivatives / Aryl alkyl ketones / Toluenes / Alpha-amino ketones / Dialkylamines / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Alkyl-phenylketone / Alpha-aminoketone / Amine / Aromatic homomonocyclic compound / Aryl alkyl ketone / Benzenoid / Benzoyl / Hydrocarbon derivative / Monocyclic benzene moiety / Organic nitrogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
amphetamines, propanone (CHEBI:59331)
Affected organisms
Not Available

Chemical Identifiers

UNII
8BA8T27317
CAS number
1189805-46-6
InChI Key
YELGFTGWJGBAQU-UHFFFAOYSA-N
InChI
InChI=1S/C11H15NO/c1-8-4-6-10(7-5-8)11(13)9(2)12-3/h4-7,9,12H,1-3H3
IUPAC Name
2-(methylamino)-1-(4-methylphenyl)propan-1-one
SMILES
CNC(C)C(=O)C1=CC=C(C)C=C1

References

General References
Not Available
Human Metabolome Database
HMDB0041923
PubChem Compound
45266826
PubChem Substance
347829232
ChemSpider
21485694
BindingDB
50236718
ChEBI
59331
ChEMBL
CHEMBL4094396
Wikipedia
Mephedrone

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableAlcohol Related Disorders / Amphetamine-Related Disorders1
1CompletedNot AvailableAmphetamine-Related Disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.715 mg/mLALOGPS
logP1.33ALOGPS
logP2.12Chemaxon
logS-2.4ALOGPS
pKa (Strongest Acidic)18.83Chemaxon
pKa (Strongest Basic)8.05Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area29.1 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity54.13 m3·mol-1Chemaxon
Polarizability20.66 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0aor-9600000000-99e304f4c8722d5f7b2f
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-01ot-0900000000-63a56a651f789a893e55
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0900000000-72c24c862242c481aca4
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0900000000-c5357ff91e06cdd98e2f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0900000000-a293b8fd331ba92afc2b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0900000000-ab08f3ff9c43c678a409
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-01ot-0900000000-0e8d2be244e2c2b90065
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-c36f9c805707cdca4596
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0005-0900000000-0a4988d65ddec4e44b3d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0900000000-03bb00bf907535516e3d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0900000000-692e09986df677e5ecc1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0900000000-33cea69ee5f543869c02
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-01ot-0900000000-888d4a226b1d533a2ea2
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-5717c7c0504ffa0c6054
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0005-0900000000-f4e14927b85bb7d9e5b4
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0900000000-3fd3aa739f1f8f082f8d
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-0900000000-f22647a4bf6593bf5169
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-029x-3900000000-5dbc7846b1d03a5448b3
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00mk-0900000000-74fd37dab4b8c06357d0
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-7900000000-7bc9a8e8cdb9c7171ba6
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00kb-2900000000-c9a9227a72836f55edd1
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9400000000-cc31573586b7dbe0a796
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-150.4218236
predicted
DarkChem Lite v0.1.0
[M-H]-140.71446
predicted
DeepCCS 1.0 (2019)
[M+H]+150.8798236
predicted
DarkChem Lite v0.1.0
[M+H]+143.49266
predicted
DeepCCS 1.0 (2019)
[M+Na]+150.1506236
predicted
DarkChem Lite v0.1.0
[M+Na]+152.19057
predicted
DeepCCS 1.0 (2019)

Drug created at October 21, 2016 03:13 / Updated at June 12, 2020 16:53